Literature DB >> 26045247

Receptor-based virtual screening protocol for drug discovery.

Nuno M F S A Cerqueira1, Diana Gesto1, Eduardo F Oliveira1, Diogo Santos-Martins1, Natércia F Brás1, Sérgio F Sousa1, Pedro A Fernandes1, Maria J Ramos2.   

Abstract

Computational aided drug design (CADD) is presently a key component in the process of drug discovery and development as it offers great promise to drastically reduce cost and time requirements. In the pharmaceutical arena, virtual screening is normally regarded as the top CADD tool to screen large libraries of chemical structures and reduce them to a key set of likely drug candidates regarding a specific protein target. This chapter provides a comprehensive overview of the receptor-based virtual screening process and of its importance in the present drug discovery and development paradigm. Following a focused contextualization on the subject, the main stages of a virtual screening campaign, including its strengths and limitations, are the subject of particular attention in this review. In all of these stages special consideration will be given to practical issues that are normally the Achilles heel of the virtual screening process.
Copyright © 2015. Published by Elsevier Inc.

Keywords:  Drug discovery; Molecular docking; Scoring functions; Search algorithms; Virtual screening

Mesh:

Substances:

Year:  2015        PMID: 26045247     DOI: 10.1016/j.abb.2015.05.011

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  26 in total

Review 1.  Docking Screens for Novel Ligands Conferring New Biology.

Authors:  John J Irwin; Brian K Shoichet
Journal:  J Med Chem       Date:  2016-03-15       Impact factor: 7.446

2.  Ultra-High-Throughput Structure-Based Virtual Screening for Small-Molecule Inhibitors of Protein-Protein Interactions.

Authors:  David K Johnson; John Karanicolas
Journal:  J Chem Inf Model       Date:  2016-01-14       Impact factor: 4.956

3.  Improving Structure-Based Virtual Screening with Ensemble Docking and Machine Learning.

Authors:  Joel Ricci-Lopez; Sergio A Aguila; Michael K Gilson; Carlos A Brizuela
Journal:  J Chem Inf Model       Date:  2021-10-15       Impact factor: 4.956

4.  Development of Novel Ecto-Nucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Inhibitors for Tumor Immunotherapy.

Authors:  Xiang Wang; Xing Lu; Daojing Yan; Yajun Zhou; Xiangshi Tan
Journal:  Int J Mol Sci       Date:  2022-06-26       Impact factor: 6.208

5.  Peptide aptamer identified by molecular docking targeting translationally controlled tumor protein in leukemia cells.

Authors:  Onat Kadioglu; Thomas Efferth
Journal:  Invest New Drugs       Date:  2016-03-14       Impact factor: 3.850

Review 6.  Modern approaches to accelerate discovery of new antischistosomal drugs.

Authors:  Bruno Junior Neves; Eugene Muratov; Renato Beilner Machado; Carolina Horta Andrade; Pedro Vitor Lemos Cravo
Journal:  Expert Opin Drug Discov       Date:  2016-05-03       Impact factor: 6.098

7.  Identification of New Potential Inhibitors of Quorum Sensing through a Specialized Multi-Level Computational Approach.

Authors:  Fábio G Martins; André Melo; Sérgio F Sousa
Journal:  Molecules       Date:  2021-04-29       Impact factor: 4.411

Review 8.  Systems Pharmacology in Small Molecular Drug Discovery.

Authors:  Wei Zhou; Yonghua Wang; Aiping Lu; Ge Zhang
Journal:  Int J Mol Sci       Date:  2016-02-18       Impact factor: 5.923

Review 9.  Molecular Modeling Targeting Transmembrane Serine Protease 2 (TMPRSS2) as an Alternative Drug Target Against Coronaviruses.

Authors:  Igor José Dos Santos Nascimento; Edeildo Ferreira da Silva-Júnior; Thiago Mendonça de Aquino
Journal:  Curr Drug Targets       Date:  2022       Impact factor: 2.937

10.  Ligand and Structure-Based Approaches for the Identification of Peptide Deformylase Inhibitors as Antibacterial Drugs.

Authors:  Jian Gao; Li Liang; Yasheng Zhu; Shengzhi Qiu; Tao Wang; Ling Zhang
Journal:  Int J Mol Sci       Date:  2016-07-15       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.